Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

N/ANo Longer AvailableNCT04137822

Impatients N.V. trading as myTomorrows

Overview

An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.

IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms. Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).

Study Type

EXPANDED_ACCESS

Conditions

Pancreas Cancer Pancreatic Cancer Pancreatic Cancer Stage IV Pancreatic Cancer Stage III

Interventions

IMM-101BIOLOGICAL

IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: This Expanded Access Program is available for patients of 18 years or older with advanced pancreatic cancer for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable. Exclusion Criteria: Female patient of child-bearing potential who is not, in the opinion of the physician, using an approved method of birth control (e.g., physical barrier \[patient and partner\], contraceptive pill or patch, spermicide and barrier, or intrauterine device \[IUD\]).

Locations (2)

France

Paris, France

London, United Kingdom

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.